
- Volume 0 0
Lithium Carbonate ER
Roxane Laboratories Inc (Columbus,Ohio) recently announced the approval ofLithium Carbonate Extended ReleaseTablets USP, 450 mg. This product is ABratedto GlaxoSmithKline?s Eskalith CR(lithium carbonate) 450 mg. LithiumCarbonate Extended Release Tablets areindicated for the treatment of manicepisodes of manic?depressive illness.Maintenance therapy prevents or diminishesthe intensity of subsequentepisodes in those manic?depressivepatients with a history of mania. Thetablets may produce a normalization ofsymptomatology within 1 to 3 weeks. Formore information, visit www.roxane.com.
Articles in this issue
almost 22 years ago
Interface Speeds Up Prescription Fillingalmost 22 years ago
New Technologies Top Surveyalmost 22 years ago
Partnership Addresses Packaging Solutionsalmost 22 years ago
PDX Software Gets High Marksalmost 22 years ago
Polar Powder Cold Pak with Magnetic Therapyalmost 22 years ago
Seal•ONalmost 22 years ago
SaltAire Sinus Reliefalmost 22 years ago
Zim's Crack Creme Hand Sanitizeralmost 22 years ago
CoroWise Plant Sterolsalmost 22 years ago
CulturelleNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

















































































































































































































